Fulvestrant

This MedLibrary.org supplementary page on Fulvestrant is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Fulvestrant
Systematic (IUPAC) name
13-methyl-7-[9-( 4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]- 7,8,9,11,12,13,14,15,16, 17-decahydro- 6H-cyclopenta[a] phenanthrene-3,17-diol
Identifiers
CAS number 129453-61-8
ATC code L02BA03
PubChem 104741
DrugBank APRD00654
Chemical data
Formula C32H47F5O3S 
Mol. mass 606.772 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 99%
Metabolism  ?
Half life 40 days
Excretion  ?
Therapeutic considerations
Pregnancy cat.

D
Legal status

Rx only
Routes Intramuscular injection

Fulvestrant, also known as ICI 182,780, and "Faslodex" is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.[1] It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

Clinical uses

Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

External links


References

  1. ^ S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36.
v • d • e
Sex hormones and related agents (primarily G03, also L02, H01C) – human endogenous in small caps
Progestogens:
(receptor)
Agonist
Antiprogestogen
Androgens:
(receptor)
Agonist
Estrogens:
(receptor)
Agonist
Antiestrogen
Gonadotropins:
(FSHR/LHCGR)
ovulation stim.
Antigonadotropin
GnRH:
(receptor)

Wikipedia content modification information:

  • This page was last modified on 3 August 2008, at 03:39.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Fulvestrant".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.